Novartis is on the move in the UK, relocating its national headquarters from Frimley in Surrey to London to get closer to the capital’s emerging life sciences cluster.
Australia continues to show the world how not to implement an electronic health records system, after health minister Greg Hunt has extended the deadline for opting out of the country’s con
Spark Therapeutics’ gene therapy for a rare inherited sight disorder, Luxturna has been approved in Europe, but there was still no word on price from marketing partner Novartis.
Novartis and Roche’s long-running battle to try to prevent off-label prescribing of Roche’s Avastin in place of their approved Lucentis product for the eye disease age-related macular degeneration
Novartis is focusing on cutting manufacturing costs for its CAR-T cancer cell therapy as the company launches it across Europe, while keeping a watching brief on ‘off-the-shelf’ therapies t
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
